Research Topics
| John R LakeSummaryAffiliation: University of Minnesota Country: USA Publications
| Collaborators
|
Detail Information
Publications
Do we really need long-term hepatitis B hyperimmune globulin? What are the alternatives?John R Lake
Gastroenterology Division, University of Minnesota, Minneapolis, MN 55455, USA
Liver Transpl 14:S23-6. 2008..4. Effective prophylaxis against HBV re-infection can now be accomplished with combination nucleoside/nucleotide anti-virals...- Differential effects of donor age in liver transplant recipients infected with hepatitis B, hepatitis C and without viral hepatitisJohn R Lake
Gastroenterology Division, University of Minnesota, Minneapolis, Minnesota, USA
Am J Transplant 5:549-57. 2005..There are clear differences in risk factors for poor outcomes based on underlying liver disease, particularly with regard to the impact of donor age... - Split-liver transplants for two adult recipients: technique of preservation of the vena cava with the right lobe graftAbhinav Humar
Department of Surgery, University of Minnesota, Minneapolis, MN 55455, USA
Liver Transpl 10:153-5. 2004 - Hepatitis B prophylaxis post-liver transplant without maintenance hepatitis B immunoglobulin therapyDilip S Nath
Department of Surgery, University of Minnesota Medical School, Minneapolis, 55455, USA
Clin Transplant 20:206-10. 2006..CONCLUSION: Longer follow-up is needed, but this regimen may represent an alternative to chronic HBIG maintenance therapy... - Hepatitis B immune globulin for life versus limited use: I favor limited duration of therapyJohn R Lake
Liver Transplantation Program, University of Minnesota, Minneapolis, MN 55455, USA
Liver Transpl 8:S90-1. 2002 - Hot-topic debate on kidney function: renal-sparing approaches are ineffectiveJohn R Lake
Division of Gastroenterology and Hepatology, University of Minnesota, Minneapolis, MN 55455, USA
Liver Transpl 17:S50-3. 2011..4. The use of CNIs in the early posttransplant period is currently essential. 5. Whether new agents will be able to provide effective immunosuppression as primary immunosuppressives remains to be proven... - The role of immunosuppression in recurrence of hepatitis CJohn R Lake
Gastroenterology Division, University of Minnesota, Minneapolis, MN 55455, USA
Liver Transpl 9:S63-6. 2003..3. Change in the degree of immunosuppression, rather than the absolute amount of immunosuppression, is bad for HCV-infected recipients. 4. Corticosteroid boluses are bad for HCV-infected recipients... - The impact of MELD allocation on simultaneous liver-kidney transplantationJulie A Thompson
Division of Gastroenterology and Hepatology, 420 Delaware Street SE MMC 36, Minneapolis, MN 55455, USA
Curr Gastroenterol Rep 11:76-82. 2009..Finally, recommendations regarding who should receive SLK transplants are reviewed... - Technique of split-liver transplant for two adult recipientsAbhinav Humar
Department of Surgery, University of Minnesota, Minneapolis, MN 55455, USA
Liver Transpl 8:725-9. 2002 - Prevention of post-transplant cardiovascular disease--report and recommendations of an ad hoc groupAndrew D Bostom
Department of Surgery, University of Minnesota, MMC-328 Mayo, Minneapolis 55455, USA
Am J Transplant 2:491-500. 2002 - Immunosuppression and outcomes of patients transplanted for hepatitis CJohn R Lake
J Hepatol 44:627-9. 2006 - Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis CRussell H Wiesner
Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Liver Transpl 11:750-9. 2005..In conclusion, the addition of MMF at discharge to tacrolimus-based immunosuppression is associated with improved long-term outcomes after liver transplantation in patients with and without HCV... - The challenging patient: HCV and alcoholic liver diseaseMichael R Lucey
Department of Medicine, University of Wisconsin, School of Medicine and Public Health, Madison, WI, USA
Liver Transpl 13:S87-8. 2007 - Differences between Caucasian, African American, and Hispanic patients with primary biliary cirrhosis in the United StatesMarion G Peters
University of California at San Francisco, San Francisco, CA 94143 0538, USA
Hepatology 46:769-75. 2007..Possible mechanisms underlying this health discrepancy are not clear, but increased awareness of PBC as a cause of chronic cholestatic liver disease is critical in evaluating non-Caucasian patients in the United States... - MELD--an imperfect, but thus far the best, solution to the problem of organ allocationJohn R Lake
J Gastrointestin Liver Dis 17:5-7. 2008 - The survival impact of liver transplantation in the MELD era, and the future for organ allocation and distributionRobert S Brown
Am J Transplant 5:203-4. 2005 - Role of tacrolimus in the evolution of liver transplantationRonald W Busuttil
Division of Liver and Pancreas Transplant, Department of Surgery, UCLA School of Medicine, Los Angeles, CA, USA
Transplantation 77:S44-51. 2004..In the decade since tacrolimus was approved for use in the United States, it has become a widely used immunosuppressant in the field of liver transplantation... - Liver transplantation for erythropoietic protoporphyria liver diseaseBrendan M McGuire
Department of Medicine, University of Alabama at Birmingham, 1530 Third Avenue South, Birmingham, AL 35294 0005, USA
Liver Transpl 11:1590-6. 2005..In conclusion, the 5-year patient survival rate in patients transplanted for EPP liver disease is good, but the recurrence of EPP liver disease appears to diminish long term graft and patient survival...